Professional Marketing briefs: December 2012

Share this article:
Novartis announces good heart drug results
Novartis announces good heart drug results

Eli Lilly is expanding its Indiana insulin manufacturing operations, marking the first expansion of the company's Indianapolis sites in more than twenty years. The company noted in a statement that the new capacity is to meet US demand.

Novartis continues to focus on making Singapore its biotech and manufacturing hub. The company announced October 31 that it was investing more than $500 million in building a manufacturing facility that will focus on drugs based on cell culture technology. The company said in a statement it expects work to wrap by 2016.

Fallout from Johnson & Johnson's disappointing Alzheimer's drug trials continue to pile up. The company is now laying off 130 employees from the San Francisco office of its Janssen Alzheimer's Immunotherapy unit, reported Pharmalot. Bapineuzumab was a joint effort that included Johnson & Johnson, Pfizer and Elan.

Pfizer is laying off 300 employees in Canada, the Canadian Broadcast Wire reported October 28. The layoffs will shrink Pfizer's northern footprint from 2,700 employees to 2,400. Most of the cuts will be at the Montreal-area headquarters.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro